Vernalis Research

V-Research-Logo

 

 

Vernalis Research represents the research activities of Vernalis plc.  With a team experienced in fragment- and structure-based drug discovery since 1997, Vernalis Research has been committed to growing its external research collaborations. External endorsement of its discovery capabilities comes from major pharma companies around the world and includes Novartis, Servier, GSK, Lundbeck, Genentech, Asahi Kasei Pharma and Taisho. Our strengths are in developing and applying the most appropriate fragment- and structure-based methods to work with our partners to solve problems in drug discovery.

With 6 development candidates generated in the past 6 years and cell active lead compounds against 15 targets, the team has worked towards repeating the recent success for internally initiated programmes such as V158866 against FAAH, for the management of neuropathic pain and V158411 against Chk1, for cancer.

For further information visit us at www.vernalis-research.com.

 

Latest News

Results Announcement for the year ended 30 June 2017

Vernalis plc (LSE: VER) today announces its audited financial results for the year ended 30 June 2017, following the year-end trading update published on 18 July 2017.

Read more ...

Fact Sheet

For more information on Vernalis, click below to download a copy of our fact sheet

 

Factsheet-Nov14

 

 

 

 

Contact Vernalis Therapeutics

T: 1-484-913-0700
F: 1-610-651 5976

Contact information
Maps and directions
Contact form

To report SUSPECTED ADVERSE REACTIONS, contact Vernalis Therapeutics, Inc. at 1-855-705-9546 and drugsafety@propharmagroup.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch